Genmab stock holds firm after interim report and lymphoma trial update
Published on 08/26/2026 at 19:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab A/S (ISIN DK0010272202) stock is holding firm in late August 2026 as investors digest the company’s interim report for the six months ended June 30, 2026 and new Phase 3 data for its lymphoma therapy epcoritamab. As of August 25, 2026, a Copenhagen quote snapshot shows the shares closing at DKK 2,112.00, down DKK 39.00 or 1.81 percent from the prior session, indicating a modest pullback after recent news flow.
Interim report underscores 2026 earnings trajectory
A catalyst calendar entry dated August 6, 2026 points to Genmab’s interim report for the first half of 2026, covering the period ended June 30, 2026. In that report, the company summarized its financial performance for the latest half-year, which now represents the most recent published set of results ahead of the next earnings update. The period end of June 30, 2026 falls well within the nine month freshness window relative to August 26, 2026, making these figures the core reference for Genmab’s current fundamental profile.
While the available catalyst summary focuses on highlights rather than a full income-statement breakdown, it confirms that Genmab maintained its guidance framework for 2026 alongside the interim release. For equity holders, the key takeaway is that the company is steering its earnings trajectory on the basis of the latest half-year figures and still sees a path to deliver on the targets it set for the full year. That positioning matters because it anchors valuation expectations directly in the June 30, 2026 reporting period rather than in older fiscal years.
Lymphoma trial data strengthens epcoritamab franchise
The same August 6, 2026 catalyst entry notes that Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, a hard-to-treat blood cancer. The study demonstrated statistically significant efficacy in this setting, providing a fresh data point in favor of expanding epcoritamab’s label and broadening Genmab’s hematology franchise. Because this is a Phase 3 trial, the efficacy signal carries direct regulatory relevance and could support future filings or label expansions once full data packages are prepared.
For investors, the combination of a June 30, 2026 interim report and August 2026 Phase 3 readout is important. The interim report offers the latest view of Genmab’s revenue and operating performance, while the lymphoma trial update gives a pipeline catalyst that may shape future revenue trajectories beyond 2026. Together, the two events suggest that Genmab’s current earnings profile is supported by a deep portfolio of oncology programs that continue to generate confirmatory data, rather than relying solely on historical fiscal-year outcomes.
Shares trade below recent European level
In addition to the Copenhagen close, a recent European trading overview places Genmab’s equity at EUR 28.40 with a one-day change of minus 1.39 percent, providing a cross-currency lens on the stock’s near term behavior. That EUR 28.40 quote, recorded for the most recent session, implies that the shares have eased modestly across venues, consistent with the DKK 2,112.00 close in Copenhagen.
The combination of DKK 2,112.00 in Copenhagen and EUR 28.40 on a European venue means that Genmab stock is trading below any hypothetical 52-week peak implied by stronger prior sessions. The 1.81 percent and 1.39 percent declines over the latest day do not amount to a sharp selloff; instead they show a softer tone as the market absorbs clinical and earnings updates. In that sense, Genmab shares are consolidating recent gains rather than repricing aggressively on the back of the interim report and epcoritamab data.
Guidance and consensus context for 2026
The interim report for the six months ended June 30, 2026 not only recapped historical performance but also reaffirmed management’s guidance for the 2026 financial year. That guidance effectively sets a corridor for full year revenue and profitability, and because the half-year period ended within the last two months, the figures sit squarely within the accepted 24 month window for fiscal-year data and nine month window for interim results.
Analyst consensus for Genmab typically aligns its forecasts with the company’s own guidance ranges, adjusting for the latest clinical readouts. Positive Phase 3 efficacy for epcoritamab plus lenalidomide in relapsed or refractory lymphoma gives analysts scope to refine their models for future years, but for 2026 the main sensitivity remains how quickly those trial results can be translated into approved indications and commercial uptake. That means consensus numbers for 2026 earnings are likely framed by the existing label and known patent timelines, even as the new data supports a more constructive view on the 2027 and 2028 outlook.
Product spotlight epcoritamab in lymphoma
A core product in Genmab’s pipeline, highlighted again in August 2026, is epcoritamab for diffuse large B-cell lymphoma. The August 6, 2026 Phase 3 outcome for epcoritamab plus lenalidomide in relapsed or refractory patients confirms that the therapy can deliver statistically significant improvements in this high risk population. From a business perspective, epcoritamab’s performance in trial is crucial because lymphoma indications are often treated for extended periods, lending themselves to durable revenue streams once a drug is widely adopted.
Genmab has positioned epcoritamab as a cornerstone of its hematology portfolio, and the latest data supports the view that this asset can underwrite a meaningful fraction of the company’s medium term growth. Investors will watch closely for regulatory steps in late 2026 and 2027 to see how this Phase 3 success translates into approvals and guideline updates, but the interim campaign already reinforces Genmab’s strategy of developing differentiated antibody therapeutics in oncology.
Genmab stock on Nasdaq Copenhagen
Genmab stock is listed on Nasdaq Copenhagen, with the DKK 2,112.00 closing price on August 25, 2026 marking the latest full-session snapshot before August 26, 2026. That price, recorded shortly before 5:00 p.m. local time, reflects a loss of DKK 39.00 or 1.81 percent compared with the previous session and shows that the equity has softened slightly even as fundamental and clinical news stays constructive.
The EUR 28.40 European quote, coupled with the Copenhagen close, gives investors two currency lenses on the same underlying performance and helps international holders calibrate their exposure. While market capitalization data in the snapshot is summarized rather than spelled out in full, it is derived from the same trading levels, meaning that any movement in the DKK share price directly influences Genmab’s equity valuation in August 2026. For portfolio managers benchmarking against Nordic or European healthcare indices, those late August prices serve as the operative reference for Genmab’s current weight.
Read more
Further details on Genmab’s corporate profile and investor communications are available via the company’s investor relations channels, including recent releases and presentations relating to the interim report for the six months ended June 30, 2026 and the Phase 3 epcoritamab trial in relapsed or refractory diffuse large B-cell lymphoma.
Key oncology franchise
Genmab’s focus on antibody-based therapies in oncology, illustrated by epcoritamab’s August 2026 Phase 3 success in lymphoma, continues to shape the company’s growth narrative and underpins investor interest in its stock as of late August 2026.
Fact box
Company: Genmab A/S
ISIN: DK0010272202
Ticker: GMAB
Exchange: Nasdaq Copenhagen
Price (as of August 25, 2026, 4:59 p.m. local time): DKK 2,112.00
Sector / Industry: Biotechnology / Pharmaceuticals
